2morrow, a digital health startup behind a clinically validated smoking cessation app SmartQuit, has teamed-up with GlaxoSmithKline to improve access to its nicotine replacement therapy. Under the deal, those using SmartQuit as part of an employer program will be able to more easily get GSK’s nicotine replacement therapy.

According to 2morrow’s co-founder and COO Jo Masterson – employers, states, and health plans that choose GSK’s Nicoderm CQ Patch option will be able to order the patches from the within app and have them delivered to their home or work.

The idea is to get clear the step of having to go to a physician to get a prescription for the patches. After a quit plan has been completed, smokers can order the patches free as long as their employer or health plan offers it.

A randomized controlled trial of 2morrow’s six month program, which uses acceptance and commitment therapy, achieved a 13 percent quit rate compared with 8 percent from a program by Tobacco Control Research division of the National Cancer Institute.

Another, bigger trial is looking to study SmartQuit among 1,600 smokers. To that end, the company received a $3.1 million, five-year grant from the National Cancer Institute. Part of this money will be used in part to update the app ahead of the trial.

[Via: MedCityNews]